Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations
- PMID: 22110406
- PMCID: PMC3217030
- DOI: 10.1371/journal.pmed.1001122
Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations
Abstract
Shekhar Saxena and colleagues summarize the recent WHO Mental Health Gap Action Programme (mhGAP) intervention guide that provides evidence-based management recommendations for mental, neurological, and substance use (MNS) disorders.
Conflict of interest statement
JLA was paid in 2007 by Lundbeck S.A. for consultancy preparation of the research protocol for a study on the diagnostic delay in first episode of depression in contact with health care centers in Spain and was paid in 2009 by Sanofi Aventis S.A. for expert testimony on the side effects of veralapride. OO is the current President of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) (
Figures
References
-
- World Health Organization. Scaling up care for mental, neurological, and substance use disorders. 2008. Available: http://www.who.int/mental_health/mhgap_final_english.pdf. Accessed 10 October 2011. - PubMed
-
- Prince M, Patel V, Saxena S, Maj M, Maselko J, et al. No health without mental health. Lancet. 2007;370:859–877. - PubMed
-
- Saxena S, Thornicroft G, Knapp M, Whiteford H. Resources for mental health: scarcity, inequity and inefficiency. Lancet. 2007;370:878–889. - PubMed
-
- Patel V, Araya R, Chatterjee S, Chisholm D, Cohen A, et al. Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet. 2007;370:991–1005. - PubMed
-
- Jacob KS, Sharan P, Mirza I, Garrido-Cumbrera M, Seedat S, et al. Mental health systems in countries: where are we now? Lancet. 2007;370:1061–1077. - PubMed